Maximizing resources to study an uncommon cancer: E2C2—Epidemiology of Endometrial Cancer Consortium

被引:0
作者
Sara H. Olson
Chu Chen
Immaculata De Vivo
Jennifer A. Doherty
Virginia Hartmuller
Pamela L. Horn-Ross
James V. Lacey
Shannon M. Lynch
Leah Sansbury
V. Wendy Setiawan
Leo J. Schouten
Xiao Ou Shu
机构
[1] Memorial Sloan-Kettering Cancer Center,Department of Epidemiology and Biostatistics
[2] Fred Hutchinson Cancer Research Center,Program in Epidemiology, Division of Public Health Sciences
[3] University of Washington,Department of Epidemiology, School of Public Health and Community Medicine
[4] University of Washington,Department of Otolaryngology: Head and Neck Surgery, School of Medicine
[5] Brigham and Women’s Hospital,Channing Laboratory, Department of Medicine
[6] Harvard Medical School,Department of Epidemiology
[7] Harvard School of Public Health,Epidemiology & Genetics Research Program, Division of Cancer Control and Population Sciences
[8] National Cancer Institute,Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics
[9] Northern California Cancer Center,Department of Preventive Medicine, Keck School of Medicine
[10] National Cancer Institute,Department of Epidemiology, GROW – School for Oncology and Developmental Biology
[11] University of Southern California,Vanderbilt Epidemiology Center
[12] Maastricht University,Department of Medicine
[13] Vanderbilt Institute of Medicine and Public Health,undefined
[14] Vanderbilt University Medical Center,undefined
[15] Vanderbilt-Ingram Cancer Center,undefined
来源
Cancer Causes & Control | 2009年 / 20卷
关键词
Endometrial cancer; Epidemiology;
D O I
暂无
中图分类号
学科分类号
摘要
Endometrial cancer affects more than 40,000 women a year in the U.S. While the association of this disease with high body mass index and sex steroid hormones is well known, there are many questions about etiology that have not been resolved. Little is known about the genetic basis for risk associated with hormones or obesity, other common genetic factors associated with risk, or gene–environment interactions. E2C2, the Epidemiology of Endometrial Cancer Consortium, was formed in 2006 to provide a collaborative environment for addressing these questions by pooling data from existing studies. This allows for investigations of uncommon risk factors, risk for rare histologic subtypes, and associations within strata that cannot be achieved in individual studies. This report describes the establishment of the consortium, ongoing projects that demonstrate the advantages of collaborative efforts, and challenges faced. Overall, the consortium promises to provide an important means of furthering our knowledge about this cancer.
引用
收藏
页码:491 / 496
页数:5
相关论文
共 50 条
  • [41] FGFR-2 and Epithelial-Mesenchymal Transition in Endometrial Cancer
    Adamczyk-Gruszka, Olga
    Horecka-Lewitowicz, Agata
    Gruszka, Jakub
    Wawszczak-Kasza, Monika
    Strzelecka, Agnieszka
    Lewitowicz, Piotr
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [42] UBE2T is a diagnostic and prognostic biomarker for endometrial cancer
    Wang, Longyun
    Wang, Mengqi
    Wang, Zeyu
    Wang, Kai
    Zhao, Bowei
    Wang, Yue
    Zheng, Jingying
    Zhang, Shuang
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, : 2067 - 2083
  • [43] Low frequency of BRAF and CDKN2A mutations in endometrial cancer
    Salvesen, HB
    Kumar, R
    Stefansson, I
    Angelini, S
    MacDonald, N
    Smeds, J
    Jacobs, IJ
    Hemminki, K
    Das, S
    Alkslen, LA
    INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (06) : 930 - 934
  • [44] SHP2 is an independent negative prognostic factor for endometrial cancer
    Ma, Li
    Ding, Wenjing
    Teng, Yincheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 1254 - 1262
  • [45] Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer
    Chandra, Vishal
    Rai, Rajani
    Benbrook, Doris Mangiaracina
    CANCERS, 2021, 13 (10)
  • [46] Clinical and biological significance of EZH2 expression in endometrial cancer
    Roh, Ju-Won
    Choi, Jung Eun
    Han, Hee Dong
    Hu, Wei
    Matsuo, Koji
    Nishimura, Masato
    Lee, Ju-Seog
    Kwon, Sun Young
    Cho, Chi Heum
    Kim, Jongseung
    Coleman, Robert L.
    Lopez-Bernstein, Gabriel
    Sood, Anil K.
    CANCER BIOLOGY & THERAPY, 2020, 21 (02) : 147 - 156
  • [47] Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Rubinstein, Maria M.
    Doria, Eric Rios
    Konner, Jason
    Lichtman, Stuart
    Zhou, Qin
    Iasonos, Alexia
    Sarasohn, Debra
    Troso-Sandoval, Tiffany
    Friedman, Claire
    O'Cearbhaill, Roisin
    Cadoo, Karen
    Kyi, Chrisann
    Cohen, Seth
    Soldan, Krysten
    Billinson, Eric
    Caird, Imogen
    Jang, Dasom
    Eid, Khalil
    Shah, Pooja
    Guillen, Joyce
    Aghajanian, Carol
    Zamarin, Dmitriy
    Makker, Vicky
    GYNECOLOGIC ONCOLOGY, 2023, 169 : 64 - 69
  • [48] Sexual Function of Patients With Endometrial Cancer Enrolled in the Gynecologic Oncology Group LAP2 Study
    Carter, Jeanne
    Huang, Helen
    Chase, Dana M.
    Walker, Joan L.
    Cella, David
    Wenzel, Lari
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (09) : 1624 - 1633
  • [49] Significance of HER2 and VEGFR2 in Early-stage Endometrial Cancer
    An, Hyo Jung
    Song, Dae Hyun
    Kim, Yu-Min
    Jo, Hyen Chul
    Baek, Jong Chul
    Park, Ji Eun
    IN VIVO, 2022, 36 (02): : 723 - 730
  • [50] Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients
    Lambropoulou, Maria
    Papadopoulos, Nikolaos
    Tripsianis, Grigoris
    Alexiadis, George
    Pagonopoulou, Olga
    Kiziridou, Anastasia
    Liberis, Vassilios
    Kakolyris, Stylianos
    Chatzaki, Ekaterini
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (03) : 427 - 435